Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11439645 Combination therapy including a KRAS

Patent 11439645 was granted and assigned to Amgen on September, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

September 13, 2022

Patent Application Number

16687563

Date Filed

November 18, 2019

Patent Citations

US Patent 11045484 KRAS G12C inhibitors and methods of using the same

US Patent 11090304 KRAS G12C inhibitors and methods of using the same

US Patent 11053226 KRAS G12C inhibitors and methods of using the same

US Patent 11096939 KRAS G12C inhibitors and methods of using the same

US Patent 10519146 KRAS G12C inhibitors and methods of using the same

US Patent 10532042 KRAS G12C inhibitors and methods of using the same

US Patent 10640504 Inhibitors of KRAS G12C and methods of using the same

US Patent 10988485 KRAS G12C inhibitors and methods of using the same

Patent Citations Received

US Patent 12122787 Fused pyridone compound, and preparation method therefor and use thereof

0

US Patent 11905281 KRAS G12C inhibitors and methods of using the same

0

US Patent 11918584 Combination therapy including a KRAS

0

US Patent 11993597 Inhibitors of KRAS G12C and methods of using the same

0

US Patent 12083121 Substituted piperazines as KRAS G12C inhibitors

0

US Patent 11766436 KRAS G12C inhibitors and methods of using the same

Patent Primary Examiner

CPC Code

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11439645 Combination therapy including a KRAS

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool